It has been described that the use of an IGFR inhibitor caused a lower expression of this protein and a decrease in growth in pancreatic cancer cells [31,32] Thus, IGFR pathway inhibitors may avoid tumor progression in PDAC T1 proteomics subtype. This evidence concerns the gene IGF1R and neoplasm.